Scinai Immunotherapeutics Stock (NASDAQ:BVXV)
Previous Close
$1.35
52W Range
$0.63 - $11.49
50D Avg
$1.17
200D Avg
$1.79
Market Cap
$4.97M
Avg Vol (3M)
$38.94K
Beta
2.37
Div Yield
-
BVXV Company Profile
BiondVax Pharmaceuticals Ltd., a development stage biopharmaceutical company, focuses on developing, manufacturing, and commercializing products for the prevention and treatment of infectious diseases and other illnesses in Israel. The company has licensing and collaboration agreement with Max Planck Society and University Medical Center Göttingen for the development and commercialization of COVID-19 nanosized antibody (NanoAb); and development and commercialization of NanoAbs for various other disease indications. The company was incorporated in 2003 and is headquartered in Jerusalem, Israel.
BVXV Performance
Peer Comparison
| Ticker | Company |
|---|---|
| GOVX | GeoVax Labs, Inc. |
| ADIL | Adial Pharmaceuticals, Inc. |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. |
| MDWD | MediWound Ltd. |
| MLYS | Mineralys Therapeutics, Inc. |
| SABS | SAB Biotherapeutics, Inc. |
| KTTA | Pasithea Therapeutics Corp. |
| ONCT | Oncternal Therapeutics, Inc. |
| ADTX | Aditxt, Inc. |
| BLRX | BioLineRx Ltd. |
| SRZN | Surrozen, Inc. |
| RNAZ | TransCode Therapeutics, Inc. |
| FWBI | Entero Therapeutics, Inc. |
| VCNX | Vaccinex, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| ORMP | Oramed Pharmaceuticals Inc. |
| PHVS | Pharvaris N.V. |
| PEPG | PepGen Inc. |
| SLRX | Salarius Pharmaceuticals, Inc. |
| ATXI | Avenue Therapeutics, Inc. |
| MOLN | Molecular Partners AG |